Dataset Information

Salivary Proteomics and Metaproteomics Identifies Distinct Molecular and Taxonomic Signatures Of Type 2 Diabetes

ABSTRACT: Background: Saliva is an attractive body fluid for non-invasive biomarker discovery, containing both human and microbial components, associated with various chronic diseases. Type-2 diabetes (T2D) imposes a significant health and socio-economic burden. Prior research on T2D salivary microbiome utilised methods such as metagenomics, metatranscriptomics, 16S rRNA sequencing, and low-throughput proteomics. Results: We conducted ultra-fast, in-depth MS-based profiling of saliva from 15 T2D individuals and 15 age/BMI-matched healthy controls (HC). Using state-of-the-art proteomics, over 4500 proteins were identified in 21 minutes of analysis, including both human and bacterial proteins. Analysis revealed signatures of altered immune, lipid- and glucose-metabolism regulatory systems, increased oxidative stress, and possible precancerous changes in T2D saliva. Bacterial genera Neisseria and Corynebacterium showed biomarker potential, offering insights into disease pathophysiology and microbial applications for T2D management. Conclusions: This study provides a comprehensive map of salivary proteins and microbial communities, serving as a resource for better understanding of T2D pathophysiology. The identified biomarkers offer potential for improved diagnostics and therapeutic strategies in T2D and associated long-term complications.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human) Saccharomyces Cerevisiae (baker's Yeast) Saccharomyces Cerevisiae

TISSUE(S): Cell Culture, Saliva

DISEASE(S): Type 2 Diabetes Mellitus

SUBMITTER: Diana Samodova-Sommer

LAB HEAD: Atul Shahaji Deshmukh

PROVIDER: PXD051453 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20220624_TIMS6_EVO3_PRI_P0125_R0513_21min_DIA_S10_S2-B1_1_454.d.zip	Other
	20220624_TIMS6_EVO3_PRI_P0125_R0513_21min_DIA_S11_S2-B2_1_455.d.zip	Other
	20220624_TIMS6_EVO3_PRI_P0125_R0513_21min_DIA_S12_S2-B3_1_456.d.zip	Other
	20220624_TIMS6_EVO3_PRI_P0125_R0513_21min_DIA_S13_S2-B4_1_457.d.zip	Other
	20220624_TIMS6_EVO3_PRI_P0125_R0513_21min_DIA_S14_S2-B5_1_458.d.zip	Other

Items per page:

1 - 5 of 70

Publications

Salivary proteomics and metaproteomics identifies distinct molecular and taxonomic signatures of type-2 diabetes.

Samodova Diana D Stankevic Evelina E Søndergaard Mathilde Sonne MS Hu Naiyu N Ahluwalia Tarunveer S TS Witte Daniel R DR Belstrøm Daniel D Lubberding Anniek Frederike AF Jagtap Pratik D PD Hansen Torben T Deshmukh Atul S AS

Microbiome 20250110 1

<h4>Background</h4>Saliva is a protein-rich body fluid for noninvasive discovery of biomolecules, containing both human and microbial components, associated with various chronic diseases. Type-2 diabetes (T2D) imposes a significant health and socio-economic burden. Prior research on T2D salivary microbiome utilized methods such as metagenomics, metatranscriptomics, 16S rRNA sequencing, and low-throughput proteomics.<h4>Results</h4>We conducted ultrafast, in-depth MS-based proteomic and metaprote ...[more]

PMID: 39794871

Similar Datasets

Project description:Hallmarks of cystic fibrosis (CF) are increased viscosity of mucus and impaired mucociliary clearance within the airways due to mutations of the cystic fibrosis conductance regulator gene. This paves the way for the colonization by microbial pathogens and the concomitant establishment of chronic infections leading to lung tissue damage, reduced lung function, and to decreased life expectancy. Although microbial infections play a key role during disease progression, only a few studies investigated the pathophysiology of the microbial community in vivo so far. Moreover, no CF study so far applied metaproteomics, a powerful approach to unravel molecular mechanisms of microbial infection, mainly reasoned due to (I) the challenging processability of inhomogeneous, viscous, slimy sputum, and (II) the high number of human proteins masking comparably low abundant microbial proteins. Consequently, we developed a reliable, reproducible and widely applicable protocol for sputum processing, microbial enrichment, and subsequent metaproteomics analyses with a focus on microbial pathogens overcoming the aforementioned challenges. Metaproteomics data were complemented and validated by 16S sequencing, metabolomic as well as microscopic analyses. In total, we processed 21 CF sputum samples and selected three for detailed metaproteome analysis. The number of bacterial proteins/protein groups increased from 199-425 to 392-868. Moreover, our data suggest that the arginine deiminase pathway and multiple proteases and peptidases identified from various bacterial genera are so far underappreciated in their contribution to the CF pathophysiology. By providing a standardized and effective protocol for sputum processing and microbial enrichment, our study represents an important basis for future studies investigating the physiology of microbial pathogens in CF in vivo – an important prerequisite for the development of novel antimicrobial therapies against mucoviscidosis.

Project description:Pancreatic cancer is the 3rd most prevalent cause of cancer related deaths in United states alone, with over 55000 patients being diagnosed in 2019 alone and nearly as many succumbing to it. Late detection, lack of effective therapy and poor understanding of pancreatic cancer systemically contributes to its poor survival statistics. Obesity and high caloric intake linked co-morbidities like type 2 diabetes (T2D) have been attributed as being risk factors for a number of cancers including pancreatic cancer. Studies on gut microbiome has shown that lifestyle factors as well as diet has a huge effect on the microbial flora of the gut. Further, modulation of gut microbiome has been seen to contribute to effects of intensive insulin therapy in mice on high fat diet. In another study, abnormal gut microbiota was reported to contribute to development of diabetes in Db/Db mice. Recent studies indicate that microbiome and microbial dysbiosis plays a role in not only the onset of disease but also in its outcome. In colorectal cancer, Fusobacterium has been reported to promote therapy resistance. Certain intra-tumoral bacteria have also been shown to elicit chemo-resistance by metabolizing anti-cancerous agents. In pancreatic cancer, studies on altered gut microbiome have been relatively recent. Microbial dysbiosis has been observed to be associated with pancreatic tumor progression. Modulation of microbiome has been shown to affect response to anti-PD1 therapy in this disease as well. However, most of the studies in pancreatic cancer and microbiome have remained focused om immune modulation. In the current study, we observed that in a T2D mouse model, the microbiome changed significantly as the hyperglycemia developed in these animals. Our results further showed that, tumors implanted in the T2D mice responded poorly to Gemcitabine/Paclitaxel (Gem/Pac) standard of care compared to those in the control group. A metabolomic reconstruction of the WGS of the gut microbiota further revealed that an enrichment of bacterial population involved in drug metabolism in the T2D group.